- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06716073
Langsiktige resultater av endoskopisk assistert vs konvensjonell brystbevarende kirurgi hos brystkreftpasienter etter neoadjuvant terapi: en randomisert, multisenter, åpen etikett, ikke-underordnet prøvelse
With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.
Studieoversikt
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Shicheng Su
- Telefonnummer: +86-13631304227
- E-post: sushch@mail.sysu.edu.cn
Studer Kontakt Backup
- Navn: Yiwen Lu, Doctor
- Telefonnummer: +86-13268121885
- E-post: luyw8@mail.sysu.edu.cn
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510120
- Rekruttering
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Ta kontakt med:
- Shicheng Su
- Telefonnummer: +86-13631304227
- E-post: sushch@mail.sysu.edu.cn
-
Shantou, Guangdong, Kina
- Har ikke rekruttert ennå
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
-
Ta kontakt med:
- Yandan Yao
- Telefonnummer: +86-13826292688
- E-post: yaoyand@mail.sysu.edu.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ranging from 18 to 75 years
- Pathologically confirmed invasive breast cancer
- Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
- cT1-3N0-3M0
- Unilateral breast tumor
- Eastern Cooperative Oncology Group score 0-1
- Left Ventricular Ejection Fraction (LVEF) ≥50%
- Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.
Exclusion Criteria:
- Diffusely disseminated malignant calcification foci
- Not applicable for BCS after neoadjuvant therapy
- Pregnancy or breastfeeding
- Additional malignancy
- Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Endoskopisk brystbevarende kirurgi (E-BCS) gruppe
|
comparison of 2 surgical procedures |
|
Ingen inngripen: Konvensjonell brystbevarende kirurgi (C-BCS) gruppe
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
5-year disease free survival
Tidsramme: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
Patients' satisfaction with breast
Tidsramme: From surgery to the follow-up at 6 months
|
The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery |
From surgery to the follow-up at 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Surgeons' satisfaction with breast
Tidsramme: From surgery to the follow-up at 6 months
|
Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale |
From surgery to the follow-up at 6 months
|
|
Patients satisfaction with scar
Tidsramme: From surgery to the follow-up at 6 months
|
Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar |
From surgery to the follow-up at 6 months
|
|
5-year overall survival
Tidsramme: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
5-year local-regional recurrence rate
Tidsramme: From surgery to the end of follow-up at 5 years
|
The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up |
From surgery to the end of follow-up at 5 years
|
|
Postoperative complication rate
Tidsramme: From surgery to the follow-up at 12 months
|
The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma. |
From surgery to the follow-up at 12 months
|
|
Surgical duration
Tidsramme: Intraoperative
|
The time from the beginning of surgery to the end of surgery |
Intraoperative
|
|
Intraoperative blood loss
Tidsramme: Intraoperative
|
The blood loss during the operation |
Intraoperative
|
|
Incision length
Tidsramme: Intraoperative
|
The length of surgical incision |
Intraoperative
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Shicheng Su, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SYSKY-2024-648-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .